Alternatives to Kamada Pharmaceuticals

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing first-in-class oral therapy for BK polyomavirus infections.

A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.

Biotechnology company developing novel protein-based antimicrobial therapeutics.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

AI-guided drug discovery platform for tissue-targeted medicines.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Biopharmaceutical company developing novel therapeutics for cancer and other diseases using chemoproteomics and covalent chemistry.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

Biopharmaceutical company developing targeted neutrophil nanoparticle platform for chronic diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).